EUS-FNB wit or without on-site evaluation for the diagnosis of pancreatic tumor using novel 22G FNB needle: Prospective randomized controlled trial

EUS-FNB wit or without on-site evaluation for the diagnosis of pancreatic tumor using novel 22G FNB needle: Prospective randomized controlled trial - EUS-FNB with or without ROSE using 22G FNB needle: H2O study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000041676

Enrollment

180

Registered

2020-09-04

Start date

2020-08-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic tumor

Interventions

rapid on-site evaluation(ROSE) macroscopic on-site evaluation(MOSE)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: pancreatic tumor Performance status <3

Exclusion criteria

Exclusion criteria: contraindication of EUS-FNA

Design outcomes

Primary

Measure	Time frame
Diagnostic yiled	—

Countries

Japan

Contacts

Public ContactTakeshi Ogura

Osaka Medical College 2nd Department of Internal Medicine

oguratakeshi0411@yahoo.co.jp072-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026